Inicio
Markets
Charts & Ideas
Algo
Noticias
Store
Corredores
Descargar
Calendario económico
Señales Comerciales
WebTerminal
Pulse
/
para buscar: @user, $symbol, ...
Buscar
Entrada
Crear una cuenta
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
KYMR
#885
Kymera Therapeutics, Inc. Common Stock
91.350
0
+1.44%
Sector:
Básica:
Profit Currency:
Rango diario
Rango anual
Cambio diario
+1.44%
Monthly Change
+25.93%
6 month change
+54.57%
Cambio anual
+54.57%
Cierres anteriores
90.050
0
Open
91.380
0
Bid
Ask
Low
91.350
0
High
91.380
0
Volumen
150
Markets
Acciones
Atención Sanitaria
KYMR
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
64.77 M
64.94 M
65.12 M
71.5 M
71.95 M
81.64 M
—
Valuation ratios
Enterprise value
2.95 B
2.49 B
1.69 B
2.78 B
3.96 B
6 B
14.43 B
Price to earnings ratio
-20.23
-13.5
-8.8
-12.54
-15.72
-21.09
-58.15
Price to sales ratio
34.46
64.14
35
76.8
102.79
—
—
Price to cash flow ratio
-27.79
-15.52
-8.85
-13.46
-19.62
28.23
-13.71
Price to book ratio
1.23
3.61
0.64
0.97
1.27
4.16
7.04
Enterprise value to EBITDA ratio
—
-8.27
—
—
-10.77
—
—
Profitability ratios
Return on assets %
0.06
0.07
0.07
0.07
0.07
0.05
0.26
Return on equity %
0.07
0.08
0.08
0.08
0.09
0.06
0.3
Return on invested capital %
—
—
—
—
—
28.31
—
Gross margin %
100
0
0
0
0
0
0
Operating margin %
1 927.93
1 092.17
336.77
736.82
3 347.36
3 409.79
7 830.73
EBITDA margin %
—
-1 165.3
-427.5
-818.66
-3 369.61
-3 439.01
-8 054.78
Net margin %
1 670.33
956.88
296.75
667.6
2 973.05
3 029.64
6 967.04
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
8.55
7.53
8.49
8.32
7.38
10.47
34.66
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
0.01
0.02
0.01
0
0
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.66
0.82
0.99
0.74
0.31
0.79
2.83
EBIT per share
—
-1.17
-1.2
-1.19
-1.09
-1.19
-4.68
EBITDA per share
—
-1.15
-1.18
-1.17
-1.07
-1.17
-4.58
Total debt per share
—
—
—
—
—
—
—
Cash per share
7.22
6.51
5.78
8.27
5.79
10.04
29.88
Net current asset value per share
7.47
6.8
6.25
9.05
6.05
10.31
31.67
Tangible book value per share
11.73
11.14
9.81
12.08
10.84
18.7
51.42
Working capital per share
6.6
5.9
5.51
7.97
5.23
9.33
28.04
Book value per share
11.73
11.14
9.81
12.08
10.84
18.7
51.42
Noticias
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway
Morgan Stanley riduce il target di prezzo di Kymera Therapeutics
Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress
RBC Capital alza il target su Kymera Therapeutics per i progressi della pipeline
RBC Capital alza il target su Kymera Therapeutics per la pipeline
RBC Capital raises Kymera Therapeutics price target on pipeline progress
RBC Capital raises Kymera Therapeutics price target on pipeline
Stifel conferma rating Buy su Kymera Therapeutics a 114$
Stifel reiterates Buy rating on Kymera Therapeutics stock at $114
Kymera Q4 2025 slides: pipeline advances despite revenue miss
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
Kymera Therapeutics lancia un’offerta azionaria da 500 milioni di dollari